Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy
- Conditions
- Attention Deficit Hyperactivity Disorder
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 14
- Registration Number
- NCT00485550
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States
Weight Gain Management in Patients With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 74
- Registration Number
- NCT00486005
- Locations
- 🇧🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rio de Janeiro, Brazil
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
- Conditions
- Attention Deficit Hyperactivity Disorder
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 377
- Registration Number
- NCT00485407
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00482014
- Locations
- 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India
Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 37
- Registration Number
- NCT00481117
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., George, South Africa
Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2007-05-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8000
- Registration Number
- NCT00479726
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial,contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Indianapolis, Indiana, United States
Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 5
- Registration Number
- NCT00475657
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vigo, Spain
Urge Incontinence Bladder Overactivity Study
- Conditions
- Urinary Incontinence
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00475696
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North York, Ontario, Canada
Efficacy and Safety Stress Urinary Incontinence Study
- Conditions
- Urinary Incontinence, Stress
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00475358
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Duloxetine Stress Urinary Incontinence Efficacy and Safety Study
- Conditions
- Urinary Incontinence, Stress
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00475397
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of